Indeed, our findings partly support this conclusion that AnxA6 SUMOylation enhances gefitinib efficacy to reduce A431 cell growth and migration, which indicates that AnxA6 SUMOylation may be an underlying novel mechanism for the EGFR-TKI resistance in many cancers. The gene discussed is ANXA6; the disease is cancer.